This study aims to assess the effect and safety of erenumab compared to placebo for the treatment of acute posttraumatic headache (PTH) in military service members and civilians with mild traumatic brain injury (mTBI).
Male or female ≥18 and ≤50 years of age
mTBI from any cause including impact, rotational acceleration, blast, or a combination, has occurred within the prior 7 days
PTH has occurred within the prior 7 days
Able to provide informed consent
abnormal structural imaging
loss of consciousness for >30 minutes
alteration of consciousness/mental state for >24 hours 3. post-traumatic amnesia for >1 day
Participants with ongoing chronic migraine or other chronic daily headache disorders at the time of injury